You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Express Scripts
Medtronic
Dow
AstraZeneca

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 10,391,154

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,391,154
Title:Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
Abstract: Provided are Adenosine Deaminase (ADA), or a polypeptides or peptides having an ADA activity, or an ADA conjugate, pharmaceutical compositions and formulations, products of manufacture and kits, and methods containing them for the prevention and treatment of a scleroderma-associated vasculopathy, in particular proliferative obliterative vasculopathy, progressive obliterative vasculopathy or an idiopathic obliterative vasculopathy and/or preventing or decreasing the progression of scleroderma, wherein optionally the scleroderma comprises a local scleroderma or a diffuse, or a systemic scleroderma.
Inventor(s): Schreiber; Brian Dean (Oshkosh, WI), Fornasini; Gianfranco (Bethesda, MD), Soukhareva; Nadejda (Derwood, MD), Ramamurthy; Santosh Kumar (Columbia, MD)
Assignee: LEADIANT BIOSCIENCES LTD. (London, GB)
Application Number:16/037,795
Patent Claims:see list of patent claims

Details for Patent 10,391,154

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Leadiant Biosci Inc ADAGEN pegademase bovine INJECTABLE;INJECTION 019818 001 1990-11-28   Start Trial LEADIANT BIOSCIENCES LTD. (London, GB) 2037-07-19 DISCN search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial LEADIANT BIOSCIENCES LTD. (London, GB) 2037-07-19 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial LEADIANT BIOSCIENCES LTD. (London, GB) 2037-07-19 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial LEADIANT BIOSCIENCES LTD. (London, GB) 2037-07-19 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial LEADIANT BIOSCIENCES LTD. (London, GB) 2037-07-19 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Express Scripts
AstraZeneca
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.